ZoetisZTSEarnings & Financial Report
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
Revenue
$2.4B
Gross Profit
$1.7B
Operating Profit
$761.0M
Net Profit
$603.0M
Gross Margin
70.2%
Operating Margin
31.9%
Net Margin
25.3%
YoY Growth
3.0%
EPS
$1.37
Zoetis Q4 FY2025 Financial Summary
Zoetis reported revenue of $2.4B (up 3.0% YoY) for Q4 FY2025, with a net profit of $603.0M (up 3.8% YoY) (25.3% margin). Cost of goods sold was $712.0M, operating expenses totaled $914.0M.
Key Financial Metrics
| Total Revenue | $2.4B |
|---|---|
| Net Profit | $603.0M |
| Gross Margin | 70.2% |
| Operating Margin | 31.9% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Zoetis Q4 FY2025 revenue of $2.4B breaks down across 10 segments, led by Other at $1.3B (55.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other | $1.3B | 55.8% |
| Livestock | $234.0M | 9.8% |
| Pain Sedation | $209.0M | 8.8% |
| Other Pharmaceuticals | $188.0M | 7.9% |
| Swine | $125.0M | 5.2% |
| Poultry | $117.0M | 4.9% |
| Fish | $81.0M | 3.4% |
| Other Non Pharmaceuticals | $70.0M | 2.9% |
| Manufactured Product Other | $18.0M | 0.8% |
| Medicated Feed Additives | $12.0M | 0.5% |
Zoetis Revenue by Segment — Quarterly Trend
Zoetis revenue by segment across the last 4 reported quarters, showing how each business line (such as Other and Livestock) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Other | — | $1.3B | $728.0M | $827.0M |
| Livestock | $720.0M | $234.0M | — | — |
| Pain Sedation | — | $209.0M | — | — |
| Other Pharmaceuticals | — | $188.0M | — | — |
| Swine | — | $125.0M | — | — |
Zoetis Annual Revenue by Year
Zoetis annual revenue history includes year-by-year totals (for example, 2025 revenue was $9.5B).
| Year | Annual Revenue |
|---|---|
| 2025 | $9.5B |
| 2024 | $9.3B |
| 2023 | $8.5B |
| 2022 | $8.1B |
Zoetis Quarterly Revenue & Net Profit History
Zoetis results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $2.3B | +2.9% | $601.0M | 26.6% |
| Q4 FY2025 | $2.4B | +3.0% | $603.0M | 25.3% |
| Q3 FY2025 | $2.4B | +0.5% | $721.0M | 30.0% |
| Q2 FY2025 | $2.5B | +4.2% | $718.0M | 29.2% |
| Q1 FY2025 | $2.2B | +1.4% | $631.0M | 28.4% |
| Q4 FY2024 | $2.3B | +4.7% | $581.0M | 25.1% |
| Q3 FY2024 | $2.4B | +11.0% | $682.0M | 28.6% |
| Q2 FY2024 | $2.4B | +8.3% | $624.0M | 26.4% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.36B | $2.39B | $2.32B | $2.22B | $2.46B | $2.40B | $2.39B | $2.26B |
| YoY Growth | 8.3% | 11.0% | 4.7% | 1.4% | 4.2% | 0.5% | 3.0% | 2.9% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $14.16B | $14.36B | $14.24B | $14.10B | $14.48B | $15.16B | $15.47B | N/A |
| Liabilities | $9.21B | $9.12B | $9.47B | $9.44B | $9.50B | $9.76B | $12.14B | N/A |
| Equity | $4.97B | $5.23B | $4.77B | $4.66B | $4.98B | $5.40B | $3.33B | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $502.0M | $951.0M | $905.0M | $587.0M | $486.0M | $938.0M | $893.0M |